Treatment of patients with hepatitis C virus on the waiting list

Authors

  • Gregory T. Everson

    Corresponding author
    1. University of Colorado School of Medicine, University of Colorado Health Sciences Center, Denver, CO
    • University of Colorado School of Medicine, University of Colorado Health Sciences Center, 4200 E 9th Ave, B-154, Denver, CO 80262. Telephone: 303-372-8862; FAX: 303-372-8868
    Search for more papers by this author

Abstract

Key points

1. Over 90% of patients with hepatitis C on the waiting list might be candidates for therapy with interferon plus ribavirin.

2. One must exercise caution in the treatment of these patients. Those with Child-Turcotte-Pugh score >11 or Model for End-Stage Liver Disease score >25 should be excluded from treatment.

3. Sustained virologic response (hepatitis C virus RNA-negative) is mainly dependent on viral genotype, with 50% of genotype 2 and 3 patients achieving sustained virologic response.

4. The ability to achieve sustained virologic response in genotype 1 patients is dependent on dose and duration of treatment.

5. Patients rendered hepatitis C virus RNA-negative pretransplantation may not experience posttransplantation recurrence.

Ancillary